Journal article icon

Journal article

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.

Abstract:

INTRODUCTION: Type 4 phosphodiesterases (PDE4) play an important role in immune cells through the hydrolysis of the second messenger, cAMP. Inhibition of PDE4 has previously been shown to suppress immune and inflammatory responses, demonstrating PDE4 to be a valid therapeutic target for immune-mediated pathologies. We assessed the anti-inflammatory effects of a novel PDE4 inhibitor, apremilast, in human synovial cells from rheumatoid arthritis (RA) patients, as well as two murine models of a...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1186/ar3041

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Role:
Author
Expand authors...
More from this funder
Funding agency for:
Feldmann, M
Celgene Corporation More from this funder
Arthritis Research Campaign More from this funder
Publisher:
BioMed Central Publisher's website
Journal:
Arthritis Research and Therapy Journal website
Volume:
12
Issue:
3
Article number:
R107
Publication date:
2010-01-01
DOI:
EISSN:
1478-6362
ISSN:
1478-6354
Source identifiers:
224781

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP